Scholar Rock Holding EBITDA Growth & History (SRRK)
Scholar Rock Holding's calculated EBITDA was −$383.0M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$383.0M | −$132.9M | — |
| 2024 | 2024-12-31 | −$250.1M | −$81.7M | — |
| 2023 | 2023-12-31 | −$168.5M | −$37.1M | — |
| 2022 | 2022-12-31 | −$131.4M | −$4.1M | — |
| 2021 | 2021-12-31 | −$127.3M | −$41.9M | — |
| 2020 | 2020-12-31 | −$85.4M | −$32.1M | — |
| 2019 | 2019-12-31 | −$53.2M | −$3.4M | — |
| 2018 | 2018-12-31 | −$49.9M | −$25.5M | — |
| 2017 | 2017-12-31 | −$24.4M | — | — |
Scholar Rock Holding quarterly ebitda
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$108.6M | $3.1M | — |
| Q1 2026 | 2026-03-31 | −$101.7M | −$25.0M | — |
| Q4 2025 | 2025-12-31 | −$91.5M | −$22.5M | — |
| Q3 2025 | 2025-09-30 | −$103.1M | −$38.8M | — |
| Q2 2025 | 2025-06-30 | −$111.7M | −$52.7M | — |
| Q1 2025 | 2025-03-31 | −$76.7M | −$18.9M | — |
| Q4 2024 | 2024-12-31 | −$69.0M | −$21.6M | — |
| Q3 2024 | 2024-09-30 | −$64.3M | −$21.4M | — |
| Q2 2024 | 2024-06-30 | −$59.0M | −$20.6M | — |
| Q1 2024 | 2024-03-31 | −$57.8M | −$18.0M | — |
| Q4 2023 | 2023-12-31 | −$47.4M | −$7.7M | — |
| Q3 2023 | 2023-09-30 | −$43.0M | $154,000 | — |
| Q2 2023 | 2023-06-30 | −$38.4M | $4.1M | — |
| Q1 2023 | 2023-03-31 | −$39.8M | −$33.6M | — |
| Q4 2022 | 2022-12-31 | −$39.7M | −$5.0M | — |
| Q3 2022 | 2022-09-30 | −$43.1M | −$6.7M | — |
| Q2 2022 | 2022-06-30 | −$42.4M | −$12.8M | — |
| Q1 2022 | 2022-03-31 | −$6.2M | $20.4M | — |
| Q4 2021 | 2021-12-31 | −$34.6M | −$8.9M | — |
| Q3 2021 | 2021-09-30 | −$36.4M | −$13.2M | — |
| Q2 2021 | 2021-06-30 | −$29.6M | −$10.6M | — |
| Q1 2021 | 2021-03-31 | −$26.6M | −$9.3M | — |
| Q4 2020 | 2020-12-31 | −$25.8M | −$13.8M | — |
| Q3 2020 | 2020-09-30 | −$23.2M | −$6.5M | — |
| Q2 2020 | 2020-06-30 | −$19.1M | −$6.0M | — |
| Q1 2020 | 2020-03-31 | −$17.3M | −$5.9M | — |
| Q4 2019 | 2019-12-31 | −$12.0M | $3.4M | — |
| Q3 2019 | 2019-09-30 | −$16.8M | −$5.7M | — |
| Q2 2019 | 2019-06-30 | −$13.1M | $1.6M | — |
| Q1 2019 | 2019-03-31 | −$11.4M | −$2.6M | — |
| Q4 2018 | 2018-12-31 | −$15.3M | — | — |
| Q3 2018 | 2018-09-30 | −$11.0M | −$5.3M | — |
| Q2 2018 | 2018-06-30 | −$14.7M | — | — |
| Q1 2018 | 2018-03-31 | −$8.8M | — | — |
| Q3 2017 | 2017-09-30 | −$5.8M | — | — |
Scholar Rock Holding ebitda trends
Over the last five fiscal years, Scholar Rock Holding's ebitda decreased from −$85.4M to −$383.0M, a change of −$297.6M. The latest reported quarter, Q2 2026, shows −$108.6M.
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...